drugset / Trial / NCT00160732

Allogenic Islet Cell Transplantation

NCT00160732 ↗

Phase 1/2 Active not recruiting 50 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes. In addition, initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatment. The "Edmonton Protocol" of using specific anti-rejection drugs without steroids is also being evaluated.

Timeline

Start
2003-10
Primary completion
2030-10
Completion
2030-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogenic islet cells (human, U. Chicago) Unknown — Other